Most interestingly, we found that patients with GBM IDH-wildtype and EGFR amplification had a significantly better overall survival than those without EGFR amplification, only when treated with radiotherapy alone, and not when treated with chemo-radiotherapy. The gene discussed is EGFR; the disease is glioblastoma.